| Catalog Number |
TGM453715 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Vascular Dissection (3160)
|
| Date of Event |
01/10/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
| |
|
Event or Problem Description
|
|
The following information was reported to gore through the pivotal study for the gore® ascending stent graft in the treatment of lesions of the ascending aorta (asg device): on (b)(6) 2025, the patient was implanted with gore® tag® conformable thoracic stent graft with active control system to treat a thoracic aneurysm.On (b)(6) 2026, it was reported, follow up images revealed an acute type b aortic dissection without evidence of malperfusion.Anti-impulse therapy (labetalol and nicardipine) for treatment.Event is ongoing and is noted as being disease related.
|
| |
|
Event or Problem Description
|
|
Reportedly this is a new dissection, extends from distal aspect of the endovascular stent to the level of the infrarenal abdominal aorta.
|
| |
|
Additional Manufacturer Narrative
|
|
Section b.
|
| |
|
Search Alerts/Recalls
|